Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1(Oxford-AstraZeneca) and BNT162b2 (Pfizer- BioNTech) COVID-19 vaccines in the United Kingdom
Abstract: Background: Information on neurological and psychiatric adverse events following immunization (AEFIs) with COVID-19 vaccines is limited. Research design & methods: We examined and compared neurological and psychiatric AEFIS reports related to BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | Inglés |
| Publicado: |
Taylor & Francis
2022
|
| Materias: | |
| Acceso en línea: | https://repositorio.uca.edu.ar/handle/123456789/15361 |
| Aporte de: |
| id |
I33-R139-123456789-15361 |
|---|---|
| record_format |
dspace |
| spelling |
I33-R139-123456789-153612024-03-21T13:31:12Z Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1(Oxford-AstraZeneca) and BNT162b2 (Pfizer- BioNTech) COVID-19 vaccines in the United Kingdom Otero Losada, Matilde Petrovsky, Nikolai Alami, Abdallah Crispo, James A. G. Mattison, Donald Capani, Francisco Goetz, Christopher Krewski, Daniel Pérez Lloret, Santiago COVID-19 BNT162b2 VACUNAS ChAdOx1 FARMACOLOGIA NEUROLOGIA PSIQUIATRIA VIGILANCIA EFECTOS ADVERSOS Abstract: Background: Information on neurological and psychiatric adverse events following immunization (AEFIs) with COVID-19 vaccines is limited. Research design & methods: We examined and compared neurological and psychiatric AEFIS reports related to BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (Oxford-AstraZeneca) COVID-19 vaccines and recorded in the United Kingdom Medicines and Healthcare products Regulatory Agency between 9 December 2020 and 30 June 2021. Results: As of 30 June 2021, 46.1 million doses of ChAdOx1 and 30.3 million doses of BNT162b2 had been administered. The most frequently reported AEFI was headache with 1,686 and 575 cases per million doses of ChAdOx1 and BNT162b2, respectively. AEFIs more frequently reported after CHAdOx1 compared with BNT162b2 vaccination were Guillain-Barré syndrome (OR, 95% CI = 2.53, 1.82–3.51), freezing (6.66, 3.12–14.22), cluster headache (1.53, 1.28–1.84), migraine (1.23,1.17–1.30), postural dizziness (1.24,1.13–1.37), tremor (2.86, 2.68–3.05), headache (1.40, 1.38–1.43), paresthesia (1.11, 1.06–1.16), delirium (1.85, 1.45–2.36), hallucination (2.20, 1.82–2.66), poor quality sleep (1.53, 1.26–1.85), and nervousness (1.54, 1.26–1.89) Reactions less frequently reported with ChAdOx1 than with BNT162b2 were Bell’s palsy (0.47, 0.41–0.55), anosmia (0.58, 0.47–0.71), facial paralysis (0.35, 0.29– 0.41), dysgeusia (0.68, 0.62–0.73), presyncope (0.48, 0.42–0.55), syncope (0.63, 0.58–0.67), and anxiety (0.75 (0.67–0.85). Conclusion: Neurological and psychiatric AEFIs were relatively infrequent, but each vaccine was associated with a distinctive toxic profile. Plain Language Summary We examined reports on adverse neurological and psychiatric effects following immunization with BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (Oxford-AstraZeneca) for COVID-19 to the United Kingdom Medicines and Healthcare products Regulatory Agency between 9 December 2020 and 30 June 2021. Adverse effects following immunization (AEFIs) were relatively infrequent. Compared to BNT162b2, Guillain-Barré syndrome, freezing phenomenon, cluster headache, migraine, postural dizziness, tremor, headache, paresthesia, delirium, hallucination, poor quality sleep, and nervousness were more frequently reported for ChAdOx1. Reactions less frequently reported for ChAdOx1 than for BNT162b2 were Bell’s palsy, anosmia, facial paralysis, dysgeusia, presyncope, syncope, and anxiety. 2022-10-31T12:33:45Z 2022-10-31T12:33:45Z 2022 Artículo Otero Losada, M. et al. Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1(Oxford-AstraZeneca) and BNT162b2 (Pfizer- BioNTech) COVID-19 vaccines in the United Kingdom [en línea]. Expert Opinion on Drug Safety. 2022. doi: 10.1080/14740338.2022.2120607. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/15361 1474-0338 (impreso) 1744-764X (en línea) https://repositorio.uca.edu.ar/handle/123456789/15361 10.1080/14740338.2022.2120607 eng Acceso restringido http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf Taylor & Francis Expert Opinion on Drug Safety. 2022 |
| institution |
Universidad Católica Argentina |
| institution_str |
I-33 |
| repository_str |
R-139 |
| collection |
Repositorio Institucional de la Universidad Católica Argentina (UCA) |
| language |
Inglés |
| topic |
COVID-19 BNT162b2 VACUNAS ChAdOx1 FARMACOLOGIA NEUROLOGIA PSIQUIATRIA VIGILANCIA EFECTOS ADVERSOS |
| spellingShingle |
COVID-19 BNT162b2 VACUNAS ChAdOx1 FARMACOLOGIA NEUROLOGIA PSIQUIATRIA VIGILANCIA EFECTOS ADVERSOS Otero Losada, Matilde Petrovsky, Nikolai Alami, Abdallah Crispo, James A. G. Mattison, Donald Capani, Francisco Goetz, Christopher Krewski, Daniel Pérez Lloret, Santiago Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1(Oxford-AstraZeneca) and BNT162b2 (Pfizer- BioNTech) COVID-19 vaccines in the United Kingdom |
| topic_facet |
COVID-19 BNT162b2 VACUNAS ChAdOx1 FARMACOLOGIA NEUROLOGIA PSIQUIATRIA VIGILANCIA EFECTOS ADVERSOS |
| description |
Abstract: Background: Information on neurological and psychiatric adverse events following immunization
(AEFIs) with COVID-19 vaccines is limited.
Research design & methods: We examined and compared neurological and psychiatric AEFIS reports
related to BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (Oxford-AstraZeneca) COVID-19 vaccines and
recorded in the United Kingdom Medicines and Healthcare products Regulatory Agency between
9 December 2020 and 30 June 2021.
Results: As of 30 June 2021, 46.1 million doses of ChAdOx1 and 30.3 million doses of BNT162b2 had
been administered. The most frequently reported AEFI was headache with 1,686 and 575 cases
per million doses of ChAdOx1 and BNT162b2, respectively. AEFIs more frequently reported after
CHAdOx1 compared with BNT162b2 vaccination were Guillain-Barré syndrome (OR, 95% CI = 2.53,
1.82–3.51), freezing (6.66, 3.12–14.22), cluster headache (1.53, 1.28–1.84), migraine (1.23,1.17–1.30),
postural dizziness (1.24,1.13–1.37), tremor (2.86, 2.68–3.05), headache (1.40, 1.38–1.43), paresthesia
(1.11, 1.06–1.16), delirium (1.85, 1.45–2.36), hallucination (2.20, 1.82–2.66), poor quality sleep (1.53,
1.26–1.85), and nervousness (1.54, 1.26–1.89) Reactions less frequently reported with ChAdOx1 than
with BNT162b2 were Bell’s palsy (0.47, 0.41–0.55), anosmia (0.58, 0.47–0.71), facial paralysis (0.35, 0.29–
0.41), dysgeusia (0.68, 0.62–0.73), presyncope (0.48, 0.42–0.55), syncope (0.63, 0.58–0.67), and anxiety
(0.75 (0.67–0.85).
Conclusion: Neurological and psychiatric AEFIs were relatively infrequent, but each vaccine was
associated with a distinctive toxic profile.
Plain Language Summary
We examined reports on adverse neurological and psychiatric effects following immunization with
BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (Oxford-AstraZeneca) for COVID-19 to the United Kingdom
Medicines and Healthcare products Regulatory Agency between 9 December 2020 and 30 June 2021.
Adverse effects following immunization (AEFIs) were relatively infrequent. Compared to BNT162b2,
Guillain-Barré syndrome, freezing phenomenon, cluster headache, migraine, postural dizziness, tremor,
headache, paresthesia, delirium, hallucination, poor quality sleep, and nervousness were more frequently
reported for ChAdOx1. Reactions less frequently reported for ChAdOx1 than for BNT162b2
were Bell’s palsy, anosmia, facial paralysis, dysgeusia, presyncope, syncope, and anxiety. |
| format |
Artículo |
| author |
Otero Losada, Matilde Petrovsky, Nikolai Alami, Abdallah Crispo, James A. G. Mattison, Donald Capani, Francisco Goetz, Christopher Krewski, Daniel Pérez Lloret, Santiago |
| author_facet |
Otero Losada, Matilde Petrovsky, Nikolai Alami, Abdallah Crispo, James A. G. Mattison, Donald Capani, Francisco Goetz, Christopher Krewski, Daniel Pérez Lloret, Santiago |
| author_sort |
Otero Losada, Matilde |
| title |
Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1(Oxford-AstraZeneca) and BNT162b2 (Pfizer- BioNTech) COVID-19 vaccines in the United Kingdom |
| title_short |
Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1(Oxford-AstraZeneca) and BNT162b2 (Pfizer- BioNTech) COVID-19 vaccines in the United Kingdom |
| title_full |
Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1(Oxford-AstraZeneca) and BNT162b2 (Pfizer- BioNTech) COVID-19 vaccines in the United Kingdom |
| title_fullStr |
Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1(Oxford-AstraZeneca) and BNT162b2 (Pfizer- BioNTech) COVID-19 vaccines in the United Kingdom |
| title_full_unstemmed |
Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1(Oxford-AstraZeneca) and BNT162b2 (Pfizer- BioNTech) COVID-19 vaccines in the United Kingdom |
| title_sort |
disproportionality analysis of adverse neurological and psychiatric reactions with the chadox1(oxford-astrazeneca) and bnt162b2 (pfizer- biontech) covid-19 vaccines in the united kingdom |
| publisher |
Taylor & Francis |
| publishDate |
2022 |
| url |
https://repositorio.uca.edu.ar/handle/123456789/15361 |
| work_keys_str_mv |
AT oterolosadamatilde disproportionalityanalysisofadverseneurologicalandpsychiatricreactionswiththechadox1oxfordastrazenecaandbnt162b2pfizerbiontechcovid19vaccinesintheunitedkingdom AT petrovskynikolai disproportionalityanalysisofadverseneurologicalandpsychiatricreactionswiththechadox1oxfordastrazenecaandbnt162b2pfizerbiontechcovid19vaccinesintheunitedkingdom AT alamiabdallah disproportionalityanalysisofadverseneurologicalandpsychiatricreactionswiththechadox1oxfordastrazenecaandbnt162b2pfizerbiontechcovid19vaccinesintheunitedkingdom AT crispojamesag disproportionalityanalysisofadverseneurologicalandpsychiatricreactionswiththechadox1oxfordastrazenecaandbnt162b2pfizerbiontechcovid19vaccinesintheunitedkingdom AT mattisondonald disproportionalityanalysisofadverseneurologicalandpsychiatricreactionswiththechadox1oxfordastrazenecaandbnt162b2pfizerbiontechcovid19vaccinesintheunitedkingdom AT capanifrancisco disproportionalityanalysisofadverseneurologicalandpsychiatricreactionswiththechadox1oxfordastrazenecaandbnt162b2pfizerbiontechcovid19vaccinesintheunitedkingdom AT goetzchristopher disproportionalityanalysisofadverseneurologicalandpsychiatricreactionswiththechadox1oxfordastrazenecaandbnt162b2pfizerbiontechcovid19vaccinesintheunitedkingdom AT krewskidaniel disproportionalityanalysisofadverseneurologicalandpsychiatricreactionswiththechadox1oxfordastrazenecaandbnt162b2pfizerbiontechcovid19vaccinesintheunitedkingdom AT perezlloretsantiago disproportionalityanalysisofadverseneurologicalandpsychiatricreactionswiththechadox1oxfordastrazenecaandbnt162b2pfizerbiontechcovid19vaccinesintheunitedkingdom |
| _version_ |
1807949152047333376 |